AdvisorShares Psychedelics ETF [PSIL] Stock Forecast

August was an average-to-downbeat month for investors, mainly due to rising rates.

The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space.

Dr. Julie Holland on why cannabis is a psychedelic. The biggest risk in psychedelic treatment.

If you were to ask AdvisorShares Founder and CEO Noah Hamman what investors and advisors were looking for a year or two ago, he might have said “yield and income.” But now, that's changed dramatically.

There have been some exciting developments in the research around the medicinal potential of psychedelic compounds. Despite a potential opportunity for disruption, investors should keenly understand the unique risks to biotechnology plays before investing in the space.

Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.

These ETFs gained at least 15% in the downbeat month of August.

The month of August was marked by ups and downs.

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perceptions.

On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows.

AdvisorShares Psychedelics ETF is a stock and trading under the symbol PSIL

AdvisorShares Psychedelics ETF stock price is $1.3096 today.

Yes, AdvisorShares Psychedelics ETF is a publicly traded company.